VISUS, spol s.r.o.

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Diabetic eye disease6 trials
• Macular degeneration5 trials

Phase

• Phase 36 trials
• Phase 2/34 trials
• Phase 21 trial

Status

• Active, not recruiting5 trials
• Recruiting5 trials
• Not yet recruiting1 trial

Lead sponsor

• Eyebiotech Limited2 trials
• EyeBiotech Ltd.2 trials
• EyePoint Pharmaceuticals, Inc.2 trials
• Alvotech Swiss AG1 trial
• Amgen1 trial
• and 3 more

Running trials

• Recruiting

  A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

  NCT07705555· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

• Active, not recruiting

  CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  2025-523938-10-00· Phase 3· Eyepoint Inc.· Source

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

  NCT07496567· Phase 2/3· EyeBiotech Ltd.· Source

  Contact: Study Coordinator

• Recruiting

  Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema

  2025-522231-34-00· Phase 3· Alvotech Swiss AG· Source

• Active, not recruiting

  CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)

  2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration4 recruiting
• Diabetic eye disease2 recruiting